Table 1.
Demographic details and assessment instrument scores of participants.
| Measure | Patients | Controls |
|---|---|---|
| Age (y) | 33.6 ± 10.3 | 34.1 ± 10.9 |
| Sex (N females; N males) | 8; 22 | 8; 22 |
| Disease duration (mo) | 106.9 ± 90.9 | N.A. |
| Medication (mg chlorpromazine/day equivalent) | 678.8 ± 416.1 | N.A. |
| PANSS total score | 50.6 ± 11.8 | N.A. |
| PANSS positive symptoms subscale | 11.73 ± 3.62 | N.A. |
| PANSS negative symptoms subscale | 14.13 ± 5.87 | N.A. |
| PANSS general symptoms subscale | 24.76 ± 5.55 | N.A. |
| CDSS | 0.07 ± 0.25 | N.A. |
| CGI | 4.07 ± 0.98 | N.A. |
| SOFAS | 56.53 ± 13.81 | N.A. |
Note: CDSS, Calgary Depression Rating Scale for Schizophrenia; CGI, Clinical Global Impression-scale; PANSS, Positive and Negative Syndrome Scale for Schizophrenia; SOFAS, Social and Occupational Functioning Assessment Scale; N.A.: not applicable. Mean ± SD are shown except if otherwise stated.